Ceramide As A Potential Tumor Marker For Diagnosis Of Prostate Cancer And Its Association With Lipid Profile

Abstract

Background: Prostate cancer (PCa) is the second most frequent type of malignancy cancer among men worldwide. Ceramides are fatty acid derivatives of sphingoid bases, and formed not only through the de novo biosynthetic pathway, but also from the degradation of glycosphingolipids (GSLs) and ceramide-1-phosphate. Dyslipidaemia is part of metabolic syndrome, characterized by an alteration of the plasma lipid profile, including Cholesterol, HDL, and triglyceride levels. Objective Evaluate serum ceramide as tumer marker of prostate cancer and its association with lipid profile. Method This case- control study was carried out at Department of Biochemistry, College of Medicine, University of Baghdad and at Urology department, Ghazi Al-Hariri Hospital for surgical speciality during the period from March 2022 to May 2023. It included 120 men patients, 60 men patients who newly diagnosed to have primary prostate cancer (PCa), and 60 men were apparently healthy men. Investigations included serum measurements of ceramide by using enzyme linked immunosorbent assay(ELISA) and also measurement of lipid profile by using semi-auto biochemistry  analyzer.Results The results of the present study showed that there was a significant differences in ceramide in prostate cancer patients as compared with the control group The results also showed that the S.Cholesterol, and S.Triglyceride were higher in the patients group compared to the controls group  with significant statistical difference. Conclusion. According to the results obtained we can suggest that higher levels of ceramide, Cholesterol and Triglyceride may be associated with risk of prostate cancer.